Ribociclib/ET versus Chemotherapy in Premenopausal Patients: RIGHT Choice
Timothy Pluard, MD, discusses recent data from an age-based subgroup analysis of RIGHT Choice, which compares the efficacy of combination ribociclib/ET versus chemotherapy in the first-line treatment of HR+/HER2- advanced breast cancer.
Timothy Pluard Komal Jhaveri Hr Her2 Breast Cancer Real World Data Cdk4 6 Inhibitors Aromatase Inhibitors
Source: onclive.com